ライフサイエンスコーパス: antepartum

1 rtum, where there is higher risk compared to antepartum.

2 the stillbirths, 54.5% were estimated to be antepartum.

3 ance was found to be significantly increased antepartum (1028+/-231 mL/min) versus postpartum (707+/-

4 differences in reported hospitalization for antepartum (49.8% versus 45.1%, p = 0.37), intrapartum (

5 Reported antepartum (69.4%, intervention; 79.2%, control; p = 0.1

6 Antepartum admission for infection with clinical concern

7 idity, maternal quality of life, duration of antepartum admission, and antepartum or peripartum hemor

8 tient Health Questionnaire depression module antepartum and 3 and 12 months postpartum.

9 dose (200 mg bid or 125 mg bid) at 31 weeks antepartum and 6 weeks postpartum.

10 re tested by QuantiFERON-gold-in-tube (QGIT) antepartum and by QGIT and tuberculin skin test (TST) at

11 re tested by QuantiFERON-gold-in-tube (QGIT) antepartum and by QGIT and tuberculin skin test (TST) at

12 first-day and early neonatal mortality, and antepartum and intrapartum stillbirth.

13 e heat and early perinatal deaths, including antepartum and intrapartum stillbirths, and deaths withi

14 ere more common in infants of mothers in the antepartum and persistent depression trajectories (6% an

15 molecular-weight heparin during the combined antepartum and post-partum periods was not associated wi

16 emiology of perinatal depression (ie, during antepartum and post-partum periods) among women residing

17 HR: 1.3, 95% CI 1.1-1.6), and when studying antepartum and postpartum depression.

18 tructed labour (76%), malpresentation (71%), antepartum and postpartum haemorrhage (70% each), and pr

19 Didanosine (ddI) pharmacokinetics in antepartum and postpartum human immunodeficiency virus (

20 perinatal depression and differences between antepartum and postpartum onset of perinatal depression

21 cute appendicitis were calculated during the antepartum and postpartum periods and were compared with

22 r limit of normal were randomized during the antepartum and postpartum periods to antiretroviral ther

23 ores were 43.7 (33.0) and 41.2 (33.7) in the antepartum and postpartum TPT initiation arms, respectiv

24 in serum to these bacteria were measured at antepartum and postpartum visits to determine the relati

25 e effect of risk factors on the incidence of antepartum and postpartum VTE in terms of ARs and incide

26 e O, A and B blood types have higher risk of antepartum and postpartum VTE, with odds ratios between

27 den regions, it is important to consider the antepartum antiretroviral regimen taken when deciding wh

28 r HIV-1 RNA load at delivery or with type of antepartum antiretroviral therapy.

29 of intrapartum nevirapine in women receiving antepartum antiretroviral therapy.

30 2.03-509.23) and placenta praevia diagnosed antepartum (aOR 65.02, 95%CI 16.58-254.96) had raised od

31 Up to 14 days of antepartum ART before enrolment was permitted.

32 sociated with preeclampsia, were measured on antepartum blood samples.

33 presence of 3 fetal transcripts in maternal antepartum blood.

34 previously identified infants with putative antepartum brain damage in this cohort and have related

35 In this study, we sought to identify antepartum characteristics that predict the de novo deve

36 We examined antepartum clinical characteristics along with measures

37 pregnant women who received care at resident antepartum clinics at Magee-Womens Hospital (Pittsburgh,

38 No antepartum complications temporally attributable to syst

39 until at least 37 weeks' gestation) or to no antepartum dalteparin (control group).

40 ontrol group), leaving 146 women assigned to antepartum dalteparin and 143 assigned to no antepartum

41 isation because of ineligibility (two in the antepartum dalteparin group and one in the control group

42 We postulated that antepartum dalteparin would reduce these complications i

43 antepartum dalteparin and 143 assigned to no antepartum dalteparin.

44 All antepartum, delivery, and postpartum patients who were h

45 2.6, and 54.0 per 100,000 deliveries for the antepartum, delivery, and postpartum periods, respective

46 7 ICU admissions from 765,598 admissions for antepartum, delivery, or postpartum conditions using app

47 % CI: 11.3-18.5%) had symptoms suggestive of antepartum depression (EDPS score >= 11) and 31.6% (95%

48 emed to be increased for postpartum than for antepartum depression (hazard ratio 2.71 (95% confidence

49 Interpersonal psychotherapy for antepartum depression appears to be an effective alterna

50 The prevalences of antepartum depression in mothers from Cote d'Ivoire and

51 up receiving interpersonal psychotherapy for antepartum depression to a parenting education control p

52 d tailored interventions to mitigate IPV and antepartum depression to address the needs of adolescent

53 The adjusted odds of antepartum depression was 2.24 higher among women who ha

54 Antepartum depression was higher among women aged 15-24

55 lence of intimate partner violence (IPV) and antepartum depression, there is limited evidence on the

56 rogram using interpersonal psychotherapy for antepartum depression.

57 to determine the association between IPV and antepartum depression.

58 Postnatal Depression Scale (EDPS) to measure antepartum depression.

59 treatment in the hierarchy of treatment for antepartum depression.

60 the use of morning bright light therapy for antepartum depression.

61 pharmacotherapy is specifically approved for antepartum depression; novel treatment approaches may be

62 antibiotic exposure or other covariates, the antepartum depressive symptom trajectory was associated

63 f breastfeeding status, mothers experiencing antepartum depressive symptoms delivered offspring who e

64 th further understanding of the in utero and antepartum diagnosis and management of infants with thes

65 ty outcome was major bleeding which included antepartum, early post-partum (within 24 h after deliver

66 Complications arising from antepartum events such as impaired umbilical blood flow

67 Recommendations for antepartum GBS detection include enriched culture with s

68 riage (OR 1.54, 95% CI 1.02-2.32; I(2)=67%), antepartum haemorrhage (1.49, 1.01-2.20; I(2)=37%), post

69 DINGS: No studies reported the prevalence of antepartum haemorrhage (APH) according to our definition

70 aevia, placental abruption, ruptured uterus, antepartum haemorrhage (odds ratio 4.47 [95% CI 1.46-13.

71 Antepartum haemorrhage was reported in 2.2% (95% CI 1.5%

72 sia received magnesium sulphate and 67% with antepartum haemorrhage who needed blood received it.

73 al disorders including placenta praevia, and antepartum haemorrhage.

74 diabetes, polyhydramnios, pre-eclampsia, and antepartum haemorrhage.

75 ficance): placenta previa/abruptio placenta/ antepartum hemorrage; non-reassuring fetal status, obstr

76 delivery (aRR, 1.15; 95% CI, 1.01-1.31) and antepartum hemorrhage or placental abruption (aRR, 1.48;

77 diabetes, preeclampsia, maternal infection, antepartum hemorrhage or placental abruption, premature

78 ge at birth, pregnancy-induced hypertension, antepartum hemorrhage, and maternal height did not alter

79 was not associated with risk of miscarriage, antepartum hemorrhage, or stillbirth, but was associated

80 eight gain (OR: 0.78; 95% CI: 0.65 to 0.91), antepartum hemorrhages (OR: 10.0; 95% CI: 2.2 to 46.9),

81 enatal visits, preterm uterine contractions, antepartum hemorrhages, placenta previae, and preterm pr

82 bed opioids only were more likely to have an antepartum hospitalization compared with those with neit

83 ion during pregnancy and are associated with antepartum hospitalization.

84 varies modestly by recognized factors during antepartum; however, women with stillbirths, preterm bir

85 leading immediate causes of fetal death were antepartum hypoxia (35.7%) and fetal infection (37.2%),

86 Antepartum immunization generated suboptimal antibody re

87 ccination of mothers who were not vaccinated antepartum improves upon the current recommendation of u

88 Venous thromboembolism occurred antepartum in five (1%) women in the intermediate-dose g

89 Clinical features of late third trimester antepartum infection were present in 9.1% (95% CI 5.6% t

90 n or equal to 1) 500 ml or 2) 1000 ml in the antepartum, intrapartum or postpartum period.

91 We compared reported prevalence of antepartum, intrapartum, and postpartum complications am

92 We compared pooled and specific reported antepartum, intrapartum, and postpartum complications be

93 outcomes may be improved through optimizing antepartum, intrapartum, and postpartum context- and ges

94 tional agencies to disaggregate estimates by antepartum, intrapartum, postpartum, and extended post-p

95 Investigations into the association of antepartum maternal infections with the pathogenesis of

96 Antepartum maternal opiate use also increased from 1.19

97 To evaluate the cost-effectiveness of antepartum maternal vaccination in the United States, we

98 Antepartum maternal vaccination incurs costs of $114,000

99 r parent postpartum is strongly dominated by antepartum maternal vaccination.

100 Treatment of antepartum mice with the soluble ligand-binding region o

101 r chronic depressive symptomatology (7%); 2) antepartum only (6%); 3) postpartum, which resolves afte

102 ighted discharges for mothers diagnosed with antepartum opiate use, within data sets including 784,19

103 Among QGIT-positive women antepartum or at delivery, 34 (12%) reverted to QGIT-neg

104 the risk of stillbirth (odds ratio comparing antepartum or intrapartum complications with no complica

105 pectant management group had higher risks of antepartum or intrapartum haemorrhage (RR 0.6, 95% CI 0.

106 Secondary maternal outcomes included antepartum or intrapartum haemorrhage, intrapartum fever

107 life, duration of antepartum admission, and antepartum or peripartum hemorrhage.

108 Maternal depression (antepartum or post partum) has been linked to negative h

109 nogenicity of PCV-10 and PPV-23 administered antepartum or postpartum.

110 differences between women who initiated IPT antepartum or postpartum.

111 tes risk factors during the index pregnancy (antepartum oral glucose tolerance, highest fasting gluco

112 acute appendicitis was 35% lower during the antepartum period [IRR, 0.65; 95% confidence interval (C

113 for rectovaginal GBS colonization during the antepartum period between weeks 35 and 37 of gestation a

114 n admitted to the intensive care unit in the antepartum period for nonobstetrical indications were in

115 etecting GBS colonization in subjects in the antepartum period from combined vaginal/rectal swab-base

116 The absolute VTE risk in the antepartum period is not above a threshold where low-mol

117 ician-level factors and interventions in the antepartum period were most frequently cited as potentia

118 a hypertensive disorder of pregnancy in the antepartum period.

119 Most SCEs (66%) occurred in the antepartum period.

120 ood type and RBC transfusion to the risks of antepartum, peripartum and postpartum VTE are reported a

121 pertension have clinical risk factors and an antepartum plasma angiogenic profile similar to those fo

122 Antepartum plasma hepatitis C virus (HCV) RNA was quanti

123 Independent antepartum predictors of postpartum diabetes were the 30

124 Antepartum prophylactic dalteparin does not reduce the o

125 randomly allocated in a 1:1 ratio to either antepartum prophylactic dose dalteparin (5000 internatio

126 Moreover, the highest tertile of the antepartum ratio of soluble fms-like tyrosine kinase 1 t

127 The antepartum ratio of soluble fms-like tyrosine kinase 1 t

128 ant HIV diagnosis, enrollment CD4 count, and antepartum regimens, was not associated with in utero/pe

129 for the detection of group B streptococci in antepartum screening samples enriched in Lim broth was c

130 The antepartum seizure rates did not differ significantly be

131 multivariable logistic regression analysis, antepartum sepsis was an independent factor associated w

132 Antepartum sepsis was associated with higher odds of pla

133 study found that pregnancies complicated by antepartum sepsis were associated with higher odds of pl

134 An increase in perinatal optimization (e.g., antepartum steroids) but with a decline in maternal heal

135 Placental insufficiency is a major cause of antepartum stillbirth and fetal growth restriction (FGR)

136 uent pregnancies, but effects on the rate of antepartum stillbirth are unknown.

137 caesarean delivery, the risk of unexplained antepartum stillbirth at or after 39 weeks' gestation is

138 The risk of antepartum stillbirth at term is higher among women 35 y

139 The antepartum stillbirth fetuses had a higher frequency of

140 The antepartum stillbirth fetuses were of lower median birth

141 We estimated the relative risk of antepartum stillbirth in second pregnancies using time-t

142 pregnancy, amniotic fluid abnormalities, or antepartum stillbirth were excluded only from the IOL gr

143 very is associated with an increased risk of antepartum stillbirth.

144 ntified more genetic abnormalities among 443 antepartum stillbirths (8.8% vs. 6.5%, P=0.02) and 67 st

145 tillbirths, OR = 1.18 (95% CI 0.71-1.95) for antepartum stillbirths and OR = 1.64 (95% CI 0.74-3.63)

146 sociated with obstetric emergencies, whereas antepartum stillbirths are associated with maternal infe

147 20633 singleton second births, there were 68 antepartum stillbirths in 17754 women previously deliver

148 pregnancies without congenital anomalies or antepartum stillbirths was included in analyses, which w

149 lities of 41.9% in all stillbirths, 34.5% in antepartum stillbirths, and 53.8% in stillbirths with an

150 n; associations strengthened when limited to antepartum stillbirths.

151 GD subtypes defined by antepartum testing results have been associated with adv

152 eproduction and other risk factors among the antepartum than the control cases.

153 Antepartum, the levels of periodontal pathogens tended t

154 We highly recommend antepartum vaccination for as many US mothers as possibl

155 esponses were higher after postpartum versus antepartum vaccination.

156 Associations with antepartum vaginal bleeding (increased risk) and preecla

157 ion, chorioamnionitis, maternal antibiotics, antepartum vaginal bleeding, and labor lasting less than

158 was used to examine the relationship between antepartum variables and glucose tolerance status postpa

159 Three antepartum variables were independent predictors of diab

160 During antepartum, varicose veins, inflammatory bowel disease (

161 e scores were higher (worse outcomes) in the antepartum versus postpartum arms (adjusted difference,

162 mized the timing of initiation of isoniazid, antepartum versus postpartum, was evaluated.

163 o-controlled study comparing 28 weeks of IPT antepartum versus postpartum, were tested by QuantiFERON

164 o-controlled study comparing 28 weeks of IPT antepartum versus postpartum, were tested by QuantiFERON

165 We evaluated associations between antepartum weight change and adverse pregnancy outcomes

166 ere used to evaluate the association between antepartum weight change and adverse pregnancy outcomes:

167 Antepartum weight gain on DTG regimens was protective ag

168 Low antepartum weight gain was associated with higher hazard

169 Insufficient antepartum weight gain was defined using Institute of Me

170 Women who received placebo antepartum were randomized at 24 weeks postpartum to PCV

171 A subset of antepartum women had longitudinal testing, with repeat t

172 Fifty outpatient antepartum women who met DSM-IV criteria for major depre

173 t broth-enriched rectal/vaginal samples from antepartum women.